Giebink G S, Schiffman G
Infect Immun. 1983 Feb;39(2):638-44. doi: 10.1128/iai.39.2.638-644.1983.
Vaccines made from the capsular polysaccharides of Streptococcus pneumoniae have been shown to reduce the incidence of pneumococcal disease in certain populations and have recently been evaluated for their ability to elicit protection against experimental pneumococcal otitis media in a chinchilla model. In this study, chinchillas were vaccinated with a dodecavalent preparation of pneumococcal capsular polysaccharides (PCP) to obtain more information on the immunogenicity of these polysaccharide antigens. All 12 PCP types elicited an antibody response, but the optimum PCP dose and the kinetics of the antibody response varied among types. Immunological paralysis was demonstrated with an immunogenic dose of PCP after primary immunization with a large PCP dose (25 micrograms or more). Pertussis vaccine acted as neither an immunoadjuvant nor an immunosuppressant in the serum antibody response to type 7F PCP in chinchillas.
由肺炎链球菌荚膜多糖制成的疫苗已被证明可降低某些人群中肺炎球菌疾病的发病率，并且最近在栗鼠模型中对其引发针对实验性肺炎球菌性中耳炎的保护能力进行了评估。在本研究中，用肺炎球菌荚膜多糖（PCP）的十二价制剂对栗鼠进行免疫接种，以获取有关这些多糖抗原免疫原性的更多信息。所有12种PCP类型均引发了抗体反应，但最佳PCP剂量和抗体反应动力学因类型而异。在用大剂量PCP（25微克或更多）进行初次免疫后，用免疫原性剂量的PCP证明了免疫麻痹。百日咳疫苗在栗鼠对7F型PCP的血清抗体反应中既不充当免疫佐剂也不充当免疫抑制剂。
